SYNTHESIS OF NEW ORLA ANTIGONADOTROPIC ANDROGENIC AGENTS

新 Orla 抗促性腺激素雄激素药物的合成

• 批准号: 3651029
• 负责人: MASATO TANABE
• 金额: $ 14.02万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-08-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3651029
• 关键词: androgen inhibitor; chemical structure function; drug administration routes; drug design /synthesis /production; male; spermatogenesis inhibitor

Conduct a comprehensive twenty-four month synthetic and scructure-activity program aimed at the development of new potent oral androgenic-antigonadotropic agents for male fertility control. The proposed new antifertility agents would act by suppressing pituitary release of the luteinizing hormone necessary for the intratesticular production of the testosterone required for spermatogenesis. The potent androgenic activity of these new agents would maintain libido andsecondary sex characteristics.

进行为期24个月的综合和结构活动 旨在开发新的强效口腔的计划 用于男性生育控制的雄激素-抗性腺激素药。这个 拟议的新抗生育药物将通过抑制脑下垂体发挥作用 睾丸内必需的促黄体激素的释放 产生精子发生所需的睾丸激素。强大的 这些新药物的雄激素活性将维持性欲和继发性 性别特征。